ARWR Arrowhead Pharmaceuticals Inc.

44.55
+0.35  (+1%)
Previous Close 44.2
Open 44.54
52 Week Low 19.5101
52 Week High 73.72
Market Cap $4,533,999,357
Shares 101,773,274
Float 73,717,058
Enterprise Value $4,205,636,114
Volume 437,657
Av. Daily Volume 1,202,622
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
ARO-HBV / JNJ-3989
Hepatitis B (HBV)
Phase 2b
Phase 2b
Phase 2b initiation announced August 28, 2019.
AROAPOC31001
Familial chylomicronemia syndrome (FCS) / Hypertriglyceridemia
Phase 1
Phase 1
Phase 1 data noted mean maximum reductions in APOC3 of 97% - February 5, 2020
AROHSD1001
Nonalcoholic steatohepatitis (NASH)
Phase 1/2
Phase 1/2
Phase 1/2 initiation announced March 3, 2020.
ARO-ANG3
Dyslipidemia
Phase 1
Phase 1
Phase 1 data released February 5, 2020. Hypercholesterolemia - mean maximum reductions in ANGPTL3 of 79-88%; Hypertriglyceridemia - mean maximum reductions in ANGPTL3 of 83%.
ARO-HIF2
Clear Cell Renal Cell Carcinoma
Phase 1b
Phase 1b
Phase 1b trial to commence dosing 1H 2020.
AROAAT2002 - Europe
AATD-associated liver disease
Phase 2
Phase 2
Phase 2 open label initiation of dosing announced December 20, 2019.
ARO-AAT
Alpha-1 Liver Disease
Phase 2/3
Phase 2/3
Phase 2/3 dosing has commenced - noted August 8, 2019.
ARC-520 injection in combination with entecavir or tenofovir
Chronic Hepititis B (HBV)
Phase 2
Phase 2
Announced that development will be discontinued - November 29, 2016.
ARC-521
Chronic Hepititis B (HBV)
Phase 1/2
Phase 1/2
Announced that development will be discontinued - November 29, 2016.
ARC-AAT
Alpha-1 antitrypsin deficiency (AATD)
Phase 2
Phase 2
Announced that development will be discontinued - November 29, 2016.

Latest News

  1. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events:

    Jefferies Virtual Healthcare Conference – June 2-4, 2020

    June 4, 2:00 p.m. EDT – Chris Anzalone, Ph.D., Arrowhead's president and CEO, will participate in a fireside chat presentation

    Goldman Sachs 41st Annual Global Healthcare Conference – June 9-11, 2020

    June 10, 11:20 a.m. EDT – Dr. Anzalone will participate in a fireside chat presentation

    A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

    About Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops…

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events:

    Jefferies Virtual Healthcare Conference – June 2-4, 2020

    June 4, 2:00 p.m. EDT – Chris Anzalone, Ph.D., Arrowhead's president and CEO, will participate in a fireside chat presentation

    Goldman Sachs 41st Annual Global Healthcare Conference – June 9-11, 2020

    June 10, 11:20 a.m. EDT – Dr. Anzalone will participate in a fireside chat presentation

    A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

    About Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

    For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

    Safe Harbor Statement under the Private Securities Litigation Reform Act:

    This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

    Source: Arrowhead Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  2. - Conference Call and Webcast Today, May 7 at 4:30 p.m. EDT

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced financial results for its fiscal second quarter ended March 31, 2020. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

    Conference Call and Webcast Details

    Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 7566917.

    A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also…

    - Conference Call and Webcast Today, May 7 at 4:30 p.m. EDT

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced financial results for its fiscal second quarter ended March 31, 2020. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

    Conference Call and Webcast Details

    Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 7566917.

    A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 7566917.

    Selected Recent Events

    • Dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the company's investigational RNAi therapeutic being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis
    • Completed enrollment of the first sequential cohort in the AROAAT2002 study, a pilot open-label, multi-dose, Phase 2 study to assess changes in a novel histological activity scale in response to ARO-AAT over time in patients with alpha-1 antitrypsin deficiency associated liver disease
    • Completed planned enrollment in AROANG1001, a Phase 1 clinical study of ARO-ANG3, the company's investigational RNAi therapeutic being developed for the treatment of mixed dyslipidemia
    • Completed discovery and optimization work and advanced ARO-Lung2, Arrowhead's investigational RNAi therapeutic being developed for the treatment of chronic obstructive pulmonary disorder (COPD), into IND-enabling studies with a planned CTA filing in the first half of 2021. ARO-Lung2 is against an undisclosed gene target and is the company's second inhaled RNAi candidate to leverage the Targeted RNAi Molecule (TRiMTM) platform to the target pulmonary epithelium
    • Started a development program to address the current novel coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens. No additional details about this program are being disclosed at this time
    • Reported interim multiple-dose results on two cardiometabolic candidates ARO-APOC3, being developed as a potential treatment for patients with severe hypertriglyceridemia, and ARO-ANG3, being developed for the treatment of mixed dyslipidemia, showing high levels of reduction in APOC3, ANGPTL3, triglycerides, and other lipid parameters
    • Completed a regulatory submission to begin a Phase 1/2a clinical trial of ARO-ENaC, the company's investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis
    • Expanded Arrowhead's senior management team with the hiring of Jim Hassard as chief commercial officer
    • Opened a second Research and Development facility in San Diego, which allows Arrowhead to tap into additional skill sets in one the country's premier biotech hubs and also expands capacity for preclinical models to do more early research work in parallel

       

    Selected Fiscal 2020 Second Quarter Financial Results

    ARROWHEAD PHARMACEUTICALS, INC.

    CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended March 31,

     

     

    Six Months Ended March 31,

     

     

    OPERATING SUMMARY

    2020

     

     

    2019

     

     

    2020

     

     

    2019

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    REVENUE

    $

    23,528,853

     

     

    $

    48,148,275

     

     

    $

    52,983,433

     

     

    $

    82,806,171

     

     

    OPERATING EXPENSES

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

    29,443,335

     

     

     

    20,798,628

     

     

     

    52,816,951

     

     

     

    38,370,671

     

     

    General and administrative expenses

     

    16,325,773

     

     

     

    5,338,955

     

     

     

    27,260,330

     

     

     

    11,478,664

     

     

    TOTAL OPERATING EXPENSES

     

    45,769,108

     

     

     

    26,137,583

     

     

     

    80,077,281

     

     

     

    49,849,335

     

     

    OPERATING INCOME (LOSS)

     

    (22,240,255

    )

     

     

    22,010,692

     

     

     

    (27,093,848

    )

     

     

    32,956,836

     

     

    OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES

     

    2,404,685

     

     

     

    1,886,290

     

     

     

    4,584,550

     

     

     

    2,977,399

     

     

    NET INCOME (LOSS)

    $

    (19,835,570

    )

     

    $

    23,896,982

     

     

    $

    (22,509,298

    )

     

    $

    35,934,235

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    NET INCOME (LOSS) PER SHARE (DILUTED)

    $

    (0.20

    )

     

    $

    0.24

     

     

    $

    (0.23

    )

     

    $

    0.37

     

     

    WEIGHTED AVERAGE SHARES OUTSTANDING (DILUTED)

     

    101,653,136

     

     

     

    98,082,644

     

     

     

    99,359,140

     

     

     

    97,214,546

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    FINANCIAL POSITION SUMMARY

    March 31,

     

     

    September 30,

     

     

     

     

     

     

     

     

     

     

     

    2020

     

     

    2019

     

     

     

     

     

     

     

     

     

     

    CASH AND CASH EQUIVALENTS

    $

    256,650,727

     

     

    $

    221,804,128

     

     

     

     

     

     

     

     

     

     

    SHORT-TERM INVESTMENTS

     

    50,959,058

     

     

     

    36,899,894

     

     

     

     

     

     

     

     

     

     

    LONG-TERM INVESTMENTS

     

    190,618,075

     

     

     

    44,175,993

     

     

     

     

     

     

     

     

     

     

    TOTAL CASH RESOURCES (CASH AND INVESTMENTS)

     

    498,227,860

     

     

     

    302,880,015

     

     

     

     

     

     

     

     

     

     

    OTHER ASSETS

     

    62,847,842

     

     

     

    46,965,422

     

     

     

     

     

     

     

     

     

     

    TOTAL ASSETS

     

    561,075,702

     

     

     

    349,845,437

     

     

     

     

     

     

     

     

     

     

    TOTAL CURRENT DEFERRED REVENUE

     

    33,174,765

     

     

     

    77,769,629

     

     

     

     

     

     

     

     

     

     

    TOTAL LONG TERM DEFERRED REVENUE

     

    -

     

     

     

    5,035,142

     

     

     

     

     

     

     

     

     

     

    OTHER LIABILITIES

     

    34,337,467

     

     

     

    23,004,414

     

     

     

     

     

     

     

     

     

     

    TOTAL LIABILITIES

     

    67,512,232

     

     

     

    105,809,185

     

     

     

     

     

     

     

     

     

     

    TOTAL STOCKHOLDERS' EQUITY

     

    493,563,470

     

     

     

    244,036,252

     

     

     

     

     

     

     

     

     

     

    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

    $

    561,075,702

     

     

    $

    349,845,437

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    SHARES OUTSTANDING

     

    101,748,107

     

     

     

    95,506,271

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    About Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

    For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

    Safe Harbor Statement under the Private Securities Litigation Reform Act:

    This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

    Source: Arrowhead Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  3. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced the retirement of Bruce Given, M.D., Arrowhead's chief operating officer and head of R&D, which was previously planned and disclosed, after a more than 30-year career in biotechnology and pharmaceutical research, development, and sales and marketing. Dr. Given's areas of responsibility have been assumed by Javier San Martin, M.D., chief medical officer, Curt Bradshaw, Ph.D., chief scientific officer, and James Hassard, chief commercial officer, all of whom report directly to Chris Anzalone, Ph.D., president and chief executive officer. Dr. Given will be retained in an advisory capacity for a period of at least one year.

    Dr. Anzalone said: "Bruce had an impressive and successful…

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced the retirement of Bruce Given, M.D., Arrowhead's chief operating officer and head of R&D, which was previously planned and disclosed, after a more than 30-year career in biotechnology and pharmaceutical research, development, and sales and marketing. Dr. Given's areas of responsibility have been assumed by Javier San Martin, M.D., chief medical officer, Curt Bradshaw, Ph.D., chief scientific officer, and James Hassard, chief commercial officer, all of whom report directly to Chris Anzalone, Ph.D., president and chief executive officer. Dr. Given will be retained in an advisory capacity for a period of at least one year.

    Dr. Anzalone said: "Bruce had an impressive and successful career and Arrowhead benefited enormously from his leadership of our R&D organization since 2011. Together with the rest of the Arrowhead team, I would like to thank Bruce and wish him our best during his retirement."

    About Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

    For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

    Safe Harbor Statement under the Private Securities Litigation Reform Act:

    This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

    Source: Arrowhead Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  4. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events:

    BofA Securities 2020 Health Care Conference – May 12-14, 2020

    May 14, 11:00 a.m. EDT – Chris Anzalone, Ph.D., Arrowhead's president and CEO, will deliver corporate presentation

    RBC Global Healthcare Conference – May 19-20, 2020

    May 20, 2:30 p.m. EDT – Dr. Anzalone will participate in a fireside chat presentation

    A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

    About Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops medicines that treat intractable…

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events:

    BofA Securities 2020 Health Care Conference – May 12-14, 2020

    May 14, 11:00 a.m. EDT – Chris Anzalone, Ph.D., Arrowhead's president and CEO, will deliver corporate presentation

    RBC Global Healthcare Conference – May 19-20, 2020

    May 20, 2:30 p.m. EDT – Dr. Anzalone will participate in a fireside chat presentation

    A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

    About Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

    For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

    Safe Harbor Statement under the Private Securities Litigation Reform Act:

    This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

    Source: Arrowhead Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  5. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 7, 2020, at 4:30 p.m. EDT to discuss its financial results for the fiscal second quarter ended March 31, 2020.

    Conference Call and Webcast Details

    Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 7566917.

    A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after…

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 7, 2020, at 4:30 p.m. EDT to discuss its financial results for the fiscal second quarter ended March 31, 2020.

    Conference Call and Webcast Details

    Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 7566917.

    A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 7566917.

    About Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

    For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

    Safe Harbor Statement under the Private Securities Litigation Reform Act:

    This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

    Source: Arrowhead Pharmaceuticals, Inc.

    View Full Article Hide Full Article
View All Arrowhead Pharmaceuticals Inc. News